Projects

ATAHC 2: Australian Trial in Acute Hepatitis C II

Funded by the National Institute of Health (NIH), Baltimore (USA), Burnet Institute and the Kirby Institute (Sydney) Baltimore (USA) undertook a study of the treatment of acute hepatitis C (HCV) with a 24-week course of pegylated interferon (modified interferon molecule administered weekly by subcutaneous injection) with or without Ribavirin.

ATAHC II involved following a longitudinal, non-randomised cohort with a treatment and non-treatment arm. Injecting drug users were not excluded from this study.

It aimed to:

  • Evaluate the safety and efficacy of pegylated-inteferon and Ribavirin combination therapy versus pegylated-interferon monotherapy among individuals with recent HCV infection.
  • Define the incidence and prevalence of hepatitis C superinfection in individuals with recent HCV infection at baseline and during the first 12 weeks of therapy in individuals with recent HCV infection at baseline and during the first 12 weeks of therapy.
  • To determine the prevalence of protease and polymerase inhibitor mutations in recently acquired HCV infection

The study was approved by Alfred Health Human Ethics and recruitment.

Timeline

2010-2015

Collaborators

The Kirby Institute, Sydney, Australia

Funding

National Institutes of Health, Baltimore, USA

Health Issue

Contact Details

For any general enquiries relating to this project, please contact:

Professor Margaret Hellard AM

Deputy Director (Programs); Adjunct Professor, Monash University, DEPM.

Telephone

+61385062304

Email

margaret.hellard@burnet.edu.au